预约演示
更新于：2025-01-14
Bisoprolol
比索洛尔
更新于：2025-01-14
概要
基本信息
药物类型 小分子化药 |
别名 Concor、Nerkardou、EMD 33 512 + [3] |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂)、β2-adrenergic receptor拮抗剂(β2-肾上腺素能受体拮抗剂) |
治疗领域 |
非在研适应症- |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H31NO4 |
InChIKeyVHYCDWMUTMEGQY-UHFFFAOYSA-N |
CAS号66722-44-9 |
关联
107
项与 比索洛尔 相关的临床试验NCT04432610
Echocardiographic Study of a Single Dose Bisoprolol Versus Nebivolol in Healthy Subjects: a Randomized, Double-blind, Cross-over Study
IRCT20120215009014N532
Effect of Bisoprolol and Metoprolol in reducing heart rate in coronary CT-angiography candidates: a double-blind randomized clinical trial
NCT06562582
STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
100 项与 比索洛尔 相关的临床结果
登录后查看更多信息
100 项与 比索洛尔 相关的转化医学
登录后查看更多信息
100 项与 比索洛尔 相关的专利（医药）
登录后查看更多信息
1,938
项与 比索洛尔 相关的文献（医药）2025-02-01AJOG global reports
Effect of maternal beta-blocker treatment on mean fetal heart rate
Article
作者: Hautier, Sarah ; Kim, Arane ; Nguyen, Thi Minh Thu ; Luton, Dominique ; Barral, Tiphaine
Background:
During pregnancy, the prescription of beta-blockers to the mother may be necessary for pre-existing chronic conditions. Their use raises concerns due to potential effects on the fetus.
Objectives:
This study aimed to investigate the impact of beta-blockers on mean fetal heart rate in pregnant women treated with these medications compared to an untreated patient group.
Study Design:
This was a retrospective case-control study involving 90 patients, divided into two groups: 45 patients on beta-blockers and 45 untreated patients. Included patients delivered singleton pregnancies after 24 weeks of gestational age at two university hospitals in Île-de-France between 2009 and 2021. They were matched based on age, parity, and gestational age at delivery. Fetal heart rate and maternal heart rate were recorded on the day of delivery. Pregnancy outcomes were studied secondarily.
Results:
There was no significant difference in mean fetal heart rate between the two groups: 87% of fetuses from mothers treated with beta-blockers had a heart rate between 110 and 150 bpm, compared to 93% of fetuses in the second group (P=.71). Among patients taking beta-blockers, the most commonly used treatment was bisoprolol.
Conclusion:
The study did not reveal a significant effect of beta-blockers on fetal heart rate. However, close monitoring and appropriate clinical management are still necessary for pregnant patients on beta-blocker treatment due to other potential implications like intra-uterine growth restriction for both the mother and the fetus.
2025-02-01CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Oroxin B Resembles Bisoprolol in Attenuating Beta1‐Adrenergic Receptor Autoantibody‐Induced Atrial Remodelling via the PTEN /AKT /mTOR Signalling Pathway
Article
作者: Zhang, Ling ; Song, Jie ; Yang, Na ; Sun, Huaxin ; Cao, Jiaru ; Wang, Qianhui ; Tang, Baopeng ; Zhou, Xianhui ; Xi, Linqiang ; Lu, Yanmei ; Shang, Luxiang
ABSTRACT:
Beta1‐adrenergic receptor autoantibodies (β1‐AAbs) promote atrial remodelling and ultimately lead to the development of atrial fibrillation (AF). Oroxin B is a natural flavonoid glycoside with a variety of biological activities, including anti‐inflammatory and autophagy‐promoting effects, and has therapeutic benefits for a variety of diseases. The aim of this study was to investigate the potential therapeutic role of Oroxin B in the development of β1‐AAb‐induced atrial fibrillation and to elucidate the underlying mechanisms involved. We established a rat model of β1‐AAb‐induced atrial fibrillation via active immunisation. The first stage was divided into three groups: the control group, the β1‐AAb group and the β1‐AAb + bisoprolol group. The second stage was divided into three groups: the control group, the β1‐AAb group and the β1‐AAb + Oroxin B group. Serum levels of β1‐AAbs, atrial tissue levels of cyclic monophosphate (cAMP), atrial electrophysiological parameters, cardiac structure and function, mitochondrial structure, autophagy levels, cardiomyocyte apoptosis and myocardial fibrosis were examined. The results showed that bisoprolol, a β1‐blocker, improved β1‐AAb‐induced atrial electrical remodelling, reduced atrial collagen deposition, ameliorated the increase in LAD and regulated the balance of autophagy and apoptosis in atrial myocytes through the PTEN/AKT/mTOR signalling pathway. Oroxin B, a PTEN agonist, can improve the impairment of autophagy homeostasis and apoptosis in atrial tissue by activating the PTEN/AKT/mTOR signalling pathway, thereby improving atrial structure and electrical remodelling. Moreover, Oroxin B may play a therapeutic role in β1AAb‐induced atrial fibrillation. In conclusion, our results demonstrate the potential therapeutic role of Oroxin B in β1AAb‐induced atrial fibrillation and the underlying mechanisms, suggesting that Oroxin B may be an effective antiarrhythmic medication.
2025-01-02IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Combined bisoprolol and trimetazidine ameliorate arsenic trioxide -induced acute myocardial injury in rats: targeting PI3K/GSK-3β/Nrf2/HO-1 and NF-κB/iNOS signaling pathways, inflammatory mediators and apoptosis
Article
作者: El-Shoura, Ehab A. M. ; Abdel-Wahab, Basel A. ; Kozman, Magy R. ; Ahmed, Yasmin M. ; Abdel-Sattar, Asmaa Ramadan
BACKGROUND:
Arsenic-trioxide (ATO) is an effective therapy for acute promyelocytic leukemia. Unfortunately, its utility is hindered by the risk of myocardial injury. Both bisoprolol (BIS) and trimetazidine (TMZ) have various pharmacological features, including anti-oxidant, anti-inflammatory, and anti-apoptotic properties.
AIM:
The cardioprotective effects of BIS and TMZ were studied, and their mechanistic role in ameliorating ATO-induced myocardial injury.
MATERIALS AND METHODS:
Forty male Wistar rats were randomly allotted into five groups as follows: normal control group (received normal saline, orally), ATO group (7.5 mg/kg, orally), BIS (8 mg/kg, orally), TMZ (60 mg/kg, orally), and finally combination group (BIS+TMZ+ATO). Following 21 days, samples of serum and cardiac tissues were obtained to perform biochemical, molecular, and histopathological investigations.
RESULTS:
The present study showed that ATO caused myocardial injury evidenced by changes in serum biomarkers (Aspatate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, creatine kinase-MB, and cardiac troponin-1), electrolyte imbalance, and lipid profiles alongside histopathologic changes. In addition, ATO administration significantly elevated malondialdehyde, nicotinamide adenine dinucleotide phosphate hydrogen oxidase, myloperoxidase, total nitrite, inducible nitric oxide synthase, tumor necrosis factor-alpha, interleukin-1β, interleukin-6, 8-Hydroxy-2'-deoxyguanosine, nuclear factor NF-kappa-B p65 subunit, glycogen synthase kinase-3 beta, and caspase-3 expression contemporaneously with down-regulation of reduced glutathione, glutathione peroxidase, superoxide dismutase, catalase, heme oxygenase 1, nuclear factor erythroid 2-related factor 2, phosphatidylinositol-3 kinase, p-PI3K, and Bcl-2 expression. Interestingly, pretreatment with BIS and TMZ significantly reversed the detrimental effects of ATO-induced myocardial injury at both cellular and molecular levels. Otherwise, combining the two drugs displayed more enhancement than each drug alone.
CONCLUSION:
The present research depicted that BIS and TMZ have the potential to protect the heart and provide therapeutic benefits by preventing acute heart injury induced by ATO. This is achieved by reversing the redox-sensitive pathway, reducing inflammation, and inhibiting apoptosis.
100 项与 比索洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心房颤动 | 日本 | 2013-06-28 | |
| 原发性高血压 | 日本 | 2013-06-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 515 | 醖觸鏇簾獵製鏇廠膚夢(襯鑰窪鏇顧構網淵艱衊) = 繭襯餘膚廠選繭襯餘齋 襯範網積獵艱製選鹹憲 (鏇鏇鑰觸艱艱鏇簾範蓋 ) 更多 | 不佳 | 2024-08-13 | |||
Placebo | 醖觸鏇簾獵製鏇廠膚夢(襯鑰窪鏇顧構網淵艱衊) = 壓蓋窪蓋鬱繭鹹繭網積 襯範網積獵艱製選鹹憲 (鏇鏇鑰觸艱艱鏇簾範蓋 ) 更多 | ||||||
N/A | 515 | 憲衊淵鹹糧鑰壓築餘構(鹹蓋衊淵膚艱觸淵獵積) = which was less than the MCID of 1.0 膚蓋選簾積鏇襯鏇鏇構 (廠遞憲顧醖範蓋廠壓憲 ) 更多 | 不佳 | 2024-05-19 | |||
Placebo | |||||||
临床4期 | 5,020 | Beta-blocker tbisoprolol | 齋繭選襯鑰製廠廠襯餘(艱窪糧築網齋鑰網齋餘) = 遞繭醖壓積蓋選顧鬱鑰 築艱廠衊顧網鏇蓋窪鏇 (艱築淵簾糧憲遞衊鑰願 ) 更多 | 不佳 | 2024-04-07 | ||
Beta-Blockers (No beta-blocker treatment) | 齋繭選襯鑰製廠廠襯餘(艱窪糧築網齋鑰網齋餘) = 齋鹹觸觸餘糧構膚襯淵 築艱廠衊顧網鏇蓋窪鏇 (艱築淵簾糧憲遞衊鑰願 ) 更多 | ||||||
N/A | 维持 | - | 製齋窪願壓製網夢鏇窪(膚壓觸艱遞鬱蓋簾範簾): P-Value = 0.83 | 积极 | 2024-04-01 | ||
N/A | - | - | Single-Pill Combination of Perindopril/Bisoprolol (SPC) | 糧網窪糧膚衊夢選憲遞(膚獵窪鏇構網觸蓋製網) = 鏇廠膚範壓憲網鑰鹽齋 齋顧淵糧鏇鑰獵夢觸積 (鏇餘網構鑰製襯糧築齋, 2.3) 更多 | 积极 | 2023-06-01 | |
Free Combination of Perindopril/Bisoprolol | 糧網窪糧膚衊夢選憲遞(膚獵窪鏇構網觸蓋製網) = 鏇鬱積廠襯選網鹽鏇鬱 齋顧淵糧鏇鑰獵夢觸積 (鏇餘網構鑰製襯糧築齋, 2.9) 更多 | ||||||
N/A | - | 5 | 積鬱繭遞鑰製觸膚膚衊(膚鬱選壓遞糧襯廠憲觸) = reduced risk of any AE and peripheral edema compared to control 鹹鏇鏇鬱遞鹹艱遞餘鹽 (廠憲夢網鹹繭遞網願築 ) 更多 | 积极 | 2023-06-01 | ||
(Control) | |||||||
临床3期 | 150 | 鏇夢膚範襯選餘製淵積(鏇糧簾鬱夢鬱遞範窪鑰) = Less treatment-related adverse events were reported in group A (1.3%) versus in group B (6.9%) 觸獵膚簾廠鬱範糧憲膚 (繭憲鏇淵夢蓋糧選艱選 ) | 积极 | 2022-06-01 | |||
N/A | 200 | Bisoprolol 5 mg | 願鬱製夢鑰遞簾襯糧鑰(鏇願糧蓋壓觸糧齋築齋) = 獵築醖鏇淵艱積鹽憲鹹 構膚壓鬱憲鏇壓遞膚衊 (糧簾襯餘鏇觸製願憲蓋 ) 更多 | - | 2021-08-27 | ||
Metoprolol-SR 50 mg | 願鬱製夢鑰遞簾襯糧鑰(鏇願糧蓋壓觸糧齋築齋) = 網範餘糧夢窪鹹襯夢遞 構膚壓鬱憲鏇壓遞膚衊 (糧簾襯餘鏇觸製願憲蓋 ) 更多 | ||||||
临床4期 | 161 | (Beta-blocker) | 窪膚膚夢窪廠壓窪鏇糧(獵範顧餘繭壓選鑰鏇衊) = 遞壓醖餘選糧淵廠壓壓 顧繭憲獵範構築夢鏇鹽 (願壓鹹醖淵蓋簾範衊構, 齋醖夢襯餘餘醖積範範 ~ 製窪窪鹹積構夢遞觸鏇) 更多 | - | 2021-06-16 | ||
(Digoxin) | 窪膚膚夢窪廠壓窪鏇糧(獵範顧餘繭壓選鑰鏇衊) = 夢顧夢構選醖糧襯築淵 顧繭憲獵範構築夢鏇鹽 (願壓鹹醖淵蓋簾範衊構, 範願範憲餘簾鹽淵網襯 ~ 壓齋鑰鑰構壓繭構齋顧) 更多 | ||||||
N/A | - | - | Highly dialyzable BB (HDBB) | 憲襯範壓鑰醖築顧壓網(廠選鏇選壓膚壓構衊餘): RR = 1.03 (95% CI, 0.88 ~ 1.22) 更多 | 不佳 | 2020-10-19 | |
Poorly dialyzable BB (PDBB) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用